Reata Pharmaceuticals Two Stories
Omaveloxolone in Patients with Friedreich’s Ataxia
Several communications between Reata Pharmaceuticals (RETA) and the FDA have taken place in the past regarding omaveloxolone for Friedreich’s Ataxia (FA) without reaching clear results that could satisfy either the Firm or the FDA. However, recent communication by the FDA seems to have finally satisfied both. Following . . .
This content is for paid subscribers.
Impacting News August 11, 2021